Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Urinary Bladder Neoplasms 1Skin Neoplasms 1Pancreatic Neoplasms 1Melanoma 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 589Cyclophosphamide 539Magnetic Resonance Spectroscopy 523Radiotherapy 506Specimen Handling 503Nivolumab 407Cisplatin 370Carboplatin 358Biopsy 304Blood Specimen Collection 295Radiosurgery 283Paclitaxel 274Surveys and Questionnaires 268Standard of Care 266Gemcitabine 265fludarabine 261Dexamethasone 258Drug Therapy 256venetoclax 246Bevacizumab 246Oxaliplatin 206Rituximab 195Capecitabine 194Radiation 189Fluorouracil 186Ipilimumab 184durvalumab 180Doxorubicin 175atezolizumab 172Etoposide 171

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × urelumab × 1 year × Clear all
NCT02451982 2026-06-01

Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Active not recruiting
76 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT02845323 2026-04-06

Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Active not recruiting
15 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02652455 2025-08-19

Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Completed
11 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡